Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
 NHF and Community News
-Industry News
 Travel Advisory

 

 

 
CSL Behring’s Helixate®FS Receives FDA Approval for Prophylaxis in Children
 

CSL Behring announced that Helixate®FS, the company’s recombinant factor VIII product, has been approved by the U.S. Food and Drug Administration (FDA) for routine prophylaxis in children with hemophilia A. The approval is for children 16 years of age or younger who do not have “pre-existing” joint damage.

The FDA approval was based on a multicenter study of 65 boys who were younger than 30 months. Magnetic resonance imaging (MRI) of joints showed that prophylactic use of the factor product yielded less joint damage than did on-demand—7% vs. 42%. Joint damage occurred most frequently in the boys’ ankles.

“Bleeding into joints, including the ankles, elbows and knees, is a concern for children with hemophilia A and their treatment providers,” said Jerry S. Powell, MD, Director of the Hemophilia Treatment Center at the University of California, Davis. “The FDA's approval of Helixate FS for routine prophylaxis is an innovation that will help our patient population effectively manage their condition. Modern treatment of hemophilia means preventing bleeding through routine prophylaxis, and we eagerly anticipate our patients reaching young adulthood with minimal joint damage and the ability to pursue normal lives.”

Source: CSL Behring news release dated August 17, 2009